Ismp Medication Error Definition
Contents |
is the definition of a medication error? What are the “ten key elements” of the medication-use system? Won’t medication errors be prevented if nurses just follow the “Five Rights?” What are "high-alert" medications? What abbreviations are dangerous? Are these ismp look alike sound alike evidence based? What drug names are frequently confused? How should tall man lettering be ismp error prone abbreviations applied to differentiate look-alike/sound-alike drug names? What is confirmation bias? How do I do an independent double check? How can I measure
What Is Medication Safety
culture? Should a healthcare practitioner be disciplined for being involved in an error? How can I assess risk? What is the difference between high-leverage and low-leverage safety strategies? What is an FMEA, and how can I
Ismp Tall Man
use it? How do I join ISMP? What ISMP resources are available for consumers? Why are standard concentrations safer than using the Rule of 6 for pediatric drips? What tools does ISMP have to satisfy regulatory or insurance network inclusion requirements for community pharmacies to demonstrate participation and knowledge in medication safe practices? Is there a way to get involved with ISMP as a student? Does ISMP have a nationally registered student-organization? ismp canada 1. What is the national medication error rate? What standards are available for benchmarking? A national or other regional medication error rate does not exist. It is not possible to establish a national medication error rate or set a benchmark for medication error rates. Each hospital or organization is different. The rates that are tracked are a measure of the number of reports at a given institution not the actual number of events or the quality of the care given. Most systems for measuring medication errors rely on voluntary reporting of errors and near-miss events. Studies have shown that even in good systems, voluntary reporting only captures the "tip of the iceberg." For this reason, counting reported errors yields limited information about how safe a medication-use process actually is. It is very possible that an institution with a good reporting system, and thus what appears to be a high error "rate," may have a safer system. For more detailed information see Medication Errors, a book available on our website, and the following articles. "If safety is your yardstick, measuring culture from the top down must be a priority" ISMP Medication Safety Alert! March 22, 2007 "Measuring up to medication safety" ISMP Medication Safety Alert! March 10, 2005 "Measuring medication safety: What works? What doesn't?
(description of the safety issue along with error-reduction recommendations) In direct response to analysis of specific types of errors and hazards submitted to the MERP, ISMP
Types Of Medication Errors
electronically distributed timely, nationwide, hazard alerts to healthcare providers on the following medication errors statistics topics: Fatal events involving concentrated electrolytes (1996) Mix-ups between various protease inhibitors, some new to the market (1996) Change in ismp definition packaging of Clintec Nutrition 10% amino acid solution, which has led to mix-ups with look-alike containers of 10% dextrose solution (1996) Errors from confusing dose labeling on Camptosar (irinotecan hydrochloride injection, CPT-11) http://www.ismp.org/faq.asp (The alert leads to labeling changes) (1996) Ambiguous presentation of a cisplatin regimen published in the Journal of Clinical Oncology (The alert leads to correction published in subsequent journal) (1997) Fatal overdoses of cisplatin due to labeling and packaging similarity with carboplatin (The alert leads to labeling and packaging changes) (1997) Fatal events involving magnesium sulfate overdoses (1997) Fatal errors stemming from confusion between lipid-based http://www.ismp.org/about/merpimpact.aspx products (amphotericin B, doxorubicin, daunorubicin) and their conventional counterparts (1998) Repeated warnings about errors from confusing dose labeling on Cerebyx (fosphenytoin) (The alert leads to labeling changes) (1998) Methotrexate overdoses due to inadvertent administration daily instead of weekly (2002) The need for immediate, nationwide replacement of Brethine (terbutaline) ampuls with available vials to avoid potentially fatal mix-ups with look-alike ampuls of Methergine (methylergonovine) (2004) Press releases to the lay and healthcare media (description of the safety issue, error-reduction strategies, and link for additional information) In direct response to analysis of specific types of errors and hazards submitted to the MERP, ISMP electronically distributed timely, nationwide press releases to the lay and healthcare media on the following topics: The risk of accidental acetaminophen overdoses in children if parents or healthcare providers fail to recognize that there are different dosage strengths available on the market (2003) Remind parents during the flu season about the risk of acetaminophen overdoses and that aspirin is not a suitable alternative for children who have fever, headaches, or other signs of a virus infection (2003) The dangerous practice of “PCA by proxy” and other risks associated with pain cont
3,800 readers who participated in our survey regarding the definition of a near miss! ISMP agrees with the https://www.ismp.org/newsletters/acutecare/articles/20090924.asp vast majority of respondents (88%) who defined a near miss as http://www.fda.gov/drugs/drugsafety/medicationerrors/ an error that happened but did not reach the patient. These errors are captured and corrected before reaching the patient, either through chance or purposefully designed system controls that have been put in place. Thus, reporting near misses can help to evaluate whether capture opportunities medication error are functioning poorly—if they are fortuitous—or functioning well—if they are part of the system design, consistently implemented, and routinely effective. Only 3% of respondents defined a near miss as an error that reached the patient but did not result in harm. Yet, this is closer to how a near miss is defined by some state reporting ismp medication error programs and the Agency for Healthcare Research and Quality (AHRQ) (www.psnet.ahrq.gov/glossary.aspx). According to the AHRQ definition, a near miss is an “event or situation that did not produce patient injury, but only because of chance.” Thus, the good fortune of not harming a patient might reflect how robust the patient is or how fortuitous a timely intervention by the provider may be. The problem with the AHRQ definition is two-fold: 1) It does not clarify whether the harmless error that resulted in the “event” or “situation” reached the patient; and 2) It fails to foster ongoing evaluation of system controls that can help capture errors or prevent patient harm once an error has reached the patient. Instead, it implies that patient harm was avoided purely by chance, giving little credence to capture and recovery opportunities that may be working well or in need of improvement. Several respondents suggested that the term near miss is a confusing misnomer, and that a near miss is really a near “
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & Veterinary Cosmetics Tobacco Products Drugs Home Drugs Drug Safety and Availability Medication Errors Medication Errors Related to Drugs Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print Within the Center for Drug Evaluation and Research (CDER), the Division of Medication Error Prevention and Analysis (DMEPA) reviews medication error reports on marketed human drugs including prescription drugs, generic drugs, and over-the-counter drugs. DMEPA uses the National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) definition of a medication error. Specifically, a medication error is "any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use."DMEPA includes a medication error prevention program staffed with healthcare professionals. Among their many duties, program staff review medication error reports sent to MedWatch, evaluate causality, and analyze the data to provide solutions to reduce the risk of medication errors to industry and others at FDA.Additionally, DMEPA prospectively reviews proprietary names, labeling, packaging, and product design prior to drug approval to help prevent medication errors.Although DMEPA encourages manufacturers to perform their due diligence when naming their drug products and we strive to avoid approving confusing proprietary names for drug products, there are cases of adverse events where a name of a marketed product is identified as a source of confusion and error. Therefore, we continue to encourage healthcare providers, patients and consumers to report all medication errors to MedWatch so that we can be made aware of potential problems related to drug names and the Agency can provide effective interventions that will minimize further errors. In some situations, changing a proprietary name while the product is marketed may be necessary to address safety issues resulting from the n